Catalog No.
EHJ14401
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Ser150
Predicted molecular weight
18.18 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>85% as determined by SDS-PAGE.
Accession
Q7Z6A9
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
B- and T-lymphocyte attenuator, BTLA, CD272, B- and T-lymphocyte-associated protein
B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer., PMID:40463377
Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study., PMID:40276504
Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients., PMID:40243455
BTLA promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma., PMID:40081944
The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation., PMID:40040475
[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy]., PMID:39799427
Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients., PMID:39768154
Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients., PMID:39592449
Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis., PMID:39386167
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients., PMID:38939518
The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators., PMID:38928307
The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients., PMID:38835768
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer., PMID:38831106
Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma., PMID:38733770
B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis., PMID:38676311
The role of the BTLA-HVEM complex in the pathogenesis of breast cancer., PMID:38483699
BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion., PMID:38418488
The BTLA-HVEM complex - The future of cancer immunotherapy., PMID:38387336
Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma., PMID:38244072
Peptides targeting the BTLA-HVEM complex can modulate T cell immune response., PMID:38128840
Clinical significance of BTLA gene expression and rs1982809 polymorphism in pan-cancer., PMID:38117093
B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease., PMID:37655751
T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines., PMID:37500142
PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish., PMID:37486225
BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation., PMID:37473684
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia., PMID:37041226
The association of BTLA gene polymorphisms with non-small lung cancer risk in smokers and never-smokers., PMID:36741370
Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2., PMID:36552785
Topical Application of Adenosine A2-Type Receptor Agonists Prevents Contact Hypersensitivity Reactions in Mice by Affecting Skin Dendritic Cells., PMID:36174716
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508
Artificial Intelligence Analysis of Celiac Disease Using an Autoimmune Discovery Transcriptomic Panel Highlighted Pathogenic Genes including BTLA., PMID:36011206
Early detection of soluble CD27, BTLA, and TIM-3 predicts the development of nosocomial infection in pediatric burn patients., PMID:35958579
BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer., PMID:35948648
The correlation of BTLA rs1982809 polymorphism with cancer susceptibility: A meta-analysis of 8634 participators., PMID:35945755
Role of BTLA/HVEM network in development of gastric cancer., PMID:35914980
Phenotypic characterization of human peripheral γδT-cell subsets in glioblastoma., PMID:35718749
The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases., PMID:35537322
Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex., PMID:35325694
Clinical Significance of BTLA and HVEM Expression on Circulating CD4+ T and CD8+ T Cells in Chronic Hepatitis B Virus Infection., PMID:35196150
Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood., PMID:34923867
High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease., PMID:34899718
BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production., PMID:34831232
Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients., PMID:34502204
[The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma]., PMID:34455749
Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes., PMID:34217699
Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery., PMID:34205742
The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases., PMID:34163466
BTLA Expression and Function Are Impaired on SLE B Cells., PMID:33968071
Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies., PMID:33890289
For research use only. Not for human or drug use.
